World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 6
Page: 280-289

LIPID-BASED NANOPARTICLES: INNOVATIVE SOLUTIONS FOR EFFECTIVE DRUG DELIVERY

Sudhansu Sekhar Behera[*1], Pruthwiraj Dash[2], Raj Rajeswaree Tripathy[3], Jyotsna Rani Behera[4], Sagarika Prusti[5], Khipti Gayatri Mallick[6]

[1]Department of Pharmaceutics, Assistant Professor, Royal College of Pharmacy and Health Sciences, Andhapasara Road, Berhampur, Ganjam, Odisha, 760002.
[2]Multi Purpose Health Worker Male, Department of Health & Family Welfare, Government of Odisha.
[3]B. Pharma, Koustuv Research Institute of Medical Science, Koustuv Technical Campus, Plot No.2, Infocity Road, Patia, Bhubaneswar - 751024, Odisha, India.
[4]Department of Pharmaceutics, Assistant Professor, Ganesh Institute of Pharmaceutical Science, Sunguda, Chandikhole, Jajpur, Odisha, 754296.
[5,6]Department of Pharmacology, Assistant Professor, Gayatri Institute of Science and Technology, Gyan Vihar, Regeda, Gunupur Rayagada, Odisha, 765022.

Article Received: 24 October 2025 | | ***Article Revised: 14 November 2025*** | | ***Article Accepted: 5 December 2025***

***Corresponding Author: Sudhansu Sekhar Behera**
Department of Pharmaceutics, Assistant Professor, Royal College of Pharmacy and Health Sciences, Andhapasara Road, Berhampur, Ganjam, Odisha, 760002.
DOI: https://doi.org/10.5281/zenodo.17896866

How to cite this Article: Sudhansu Sekhar Behera, Pruthwiraj Dash, Raj Rajeswaree Tripathy, Jyotsna Rani Behera, Sagarika Prusti, Khipti Gayatri Mallick (2025) LIPID-BASED NANOPARTICLES: INNOVATIVE SOLUTIONS FOR EFFECTIVE DRUG DELIVERY. World Journal of Pharmaceutical Science and Research, 4(6), 280-289. https://doi.org/10.5281/zenodo.17896866

ABSTRACT

Nanoparticles based on lipids appear to be an attractive approach in drug delivery to breach the area that exist in the way to efficiently deliver drugs, consequently they provide superior advantages in therapeutic delivery. The advantage of lipid-based nanostructures is that they are assembled using lipid-based materials which are biocompatible. Nanoparticles can carry heterologous drug molecules and enhance their solubility, stability and controlled release. The architecture provides the ability to traverse biological barriers and achieve targeted delivery with decreased toxicity to the human body. The efficiency of lipid-based nanoparticles in drug delivery control is achieved by various mechanisms including passive diffusion and stimuli-responsive release. In general, the use of lipid-based nanoparticles for drug delivery is a promising technology that can augment significantly the delivery of therapeutics into the clinics outperforming conventional formulations. Moreover, this approach will lead to safe and patient-friendly therapeutic interventions.

KEYWORDS: Lipid-based nanoparticles, Drug delivery systems, Solid lipid nanoparticles, Controlled release and Targeted therapy.

INTRODUCTION

Therapeutic agents continue to elude the precision, efficiency, and safety demands of modern medicine. Conventional drugs are often unable to be optimally delivered due to biological barriers, unanticipated pharmacokinetics, and collateral side effects; hence, there remains a prudent demand for enhanced drug delivery. Given this context, lipid-based nanoparticles have emerged as a promising intelligent and flexible technology for the delivery of diverse pharmaceutical compounds. The following essay aims to outline basic principles of drug delivery systems, characterize and classify lipid-based nanoparticles, and analyze their mechanisms of drug encapsulation and release. In addition, the implications of the benefits, therapeutic uses, limitations, and prospects of lipid-based nanoparticles for drug delivery will be elucidated in the succeeding discussion.

Fundamentals of Drug Delivery Systems

Drug delivery system has traditionally involved therapeutics like tablets and injectable solutions for many years. But these traditional systems are often faced with critical challenges like poor solubility for some drugs, degradation inside the body, and system toxicity due to un-targeted distributions. Some drugs that cannot penetrate the physiological barriers such as blood-brain are limited in their actions, while dosing schedules can also lead to non-steady therapeutic levels and side effects (Samimi et al., 2019). With the increased complexity in the therapeutic agents and the variety of new drugs, there is urgent need to develop drug delivery technologies that can improve drug stability, targeting and compliance. Owing to the heightening concerns regarding drug delivery today, considerable research efforts are directed towards new carriers, such as lipid nanoparticles, as platforms for more focused and efficient drug delivery.

Finally, the new advances brought by nanotechnology far from traditional means of carry drugs to cells in the body and the application of biochemical engineering techniques had evolved into lipid-based nanoparticles with their drugs carrying means such as glyceryl behenate (Utreja et al., 2020). Compared to earlier alternatives, these newer means have promised improvements in drug penetration, stability, and general applicability. Also, the advancement at this point had ensured that pharmaceutical formulations no longer obey predetermined pathways that hamper effective drug delivery and transport, thereby making the focus of drug delivery efforts shift towards optimizing the nanoparticulate means of drug delivery concerning its treatment precision, safety in patient and optimal pharmacological responses (Utreja et al., 2020).

Lipid-Based Nanoparticles: Definition and Types

Lipid-based nanoparticles belong to nanometer-scale carriers that are made by biocompatible lipids and allow the efficient packaging and specific delivery of active entities. The liposome is a type of lipid-based nanoparticle. It consists of spherical membranes formed by one or multiple bilayered lipid structures, characterized by versatile payload capabilities of both hydrophilic and hydrophobic materials. A solid lipid nanoparticle (SLN) is generated by a solid lipid matrix that maintains its state at body temperature and therefore exhibited a better stability of drug material and sustained release behavior (Xu et al., 2022). The nanostructured lipid carrier (NLC) is based on the structural design of SLNs, yet it contains both solid lipid and liquid lipid structures. It has better drug loading capacity and reduced leaking effect of the drug from the carrier. These basic classes of lipid-based nanoparticles provide unique structural characteristics, which can be fine-tuned to meet drug delivery goals while contributing to the overarching task of precision medicine (Xu et al., 2022).

Table 1: Types of Lipid-Based Nanoparticles and Their Characteristics.

Type of Nanoparticle	Structural Composition	Drug Loading Capability	Advantages	Limitations
Liposomes	Phospholipid bilayer(s) enclosing an aqueous core	Can load both hydrophilic (in core) and hydrophobic (in bilayer) drugs	High biocompatibility, flexible formulation, good membrane fusion	Can be unstable, risk of leakage, shorter shelf-life
Solid Lipid Nanoparticles (SLNs)	Solid lipid core stabilized by surfactants	Moderate drug loading (drug dispersed within solid matrix)	High stability, controlled release, protects labile drugs	Limited loading capacity due to highly ordered solid matrix
Nanostructured Lipid Carriers (NLCs)	Mixture of solid lipids + liquid lipids forming less ordered matrix	High drug loading efficiency and better encapsulation stability	Reduced drug expulsion, improved release profile, higher storage stability	Formulation complexity increases optimization requirement
Lipid Nanoparticles for Nucleic Acids (LNPs)	Ionizable lipids + cholesterol + helper lipids forming core–shell structure	Efficient encapsulation of mRNA, siRNA, DNA	Enables gene therapy and vaccine delivery, protects nucleic acids	Can trigger immune response, costly, complex manufacturing

The table-1 compares different types of lipid-based nanoparticles used in drug delivery. Liposomes can carry both water-loving and fat-loving drugs but may sometimes be unstable. Solid lipid nanoparticles (SLNs) offer better stability and controlled release, though they have limited drug loading capacity. Nanostructured lipid carriers (NLCs) improve on SLNs by mixing solid and liquid lipids, which increases drug loading and reduces leakage. Lipid nanoparticles (LNPs), commonly used for mRNA and gene therapies, provide strong protection for genetic materials but may be expensive and can sometimes trigger immune reactions. In the same manner, a comparative study between liposomes, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) evidenced both structural similarities and differences across these delivery systems. For all formulations, the use of biocompatible lipids allowed the formation of a nanoscale barrier that protects drug molecules from degradation and enables drugs and therapeutics to interact with biological membranes (Xu et al., 2022). Structurally, liposomes are characterized by concentric lipid bilayers, forming an aqueous core that encapsulates hydrophilic agents reacting with its bilayer membrane, which, in turn, also contains hydrophobic drugs. SLNs are formed by a single phase solid lipid matrix, with a dense structure that provides security for the enclosed drugs, with a more lower versatility in terms of loading. Lastly, NLCs can be built with solid and liquid lipid domains; such approach disrupts crystalline organization of SLNs and leads to increased payload and even leakage protection of drugs during storage or administration (Xu et al., 2022).

Additionally, the physicochemical factors for drug delivery also play a vital role in the performance of lipid-based nanoparticles. Their smaller particle size (nanometer range) allow them to penetrate across cellular membranes and increase the bioavailability of the enclosed drugs or agents. The surface charge and hydrophobicity of lipid-based nanoparticles can be tailored to improve the drug loading efficacy, enhance the circulation time, and stimulate the interaction between the selected drug and their intended biological targets (Musielak et al., 2022). Also, the lipid formulations and the internal design structure impart stability to the unstable drugs by protecting them from the enzymatic degradation and environmental perturbation. These factors combinedly permit the lipid-based nanoparticles

to provide a controlled and sustained release profile for drugs, resulting in more consistent and predictable therapeutic outcomes in clinical applications (Musielak et al., 2022).

Mechanisms of Drug Encapsulation and Release

The drug is embedded into a lipid-based nanoparticle by adding the pharmaceutical compound to the core or matrix during the formulation/production step using various techniques such as high-shear homogenization or solvent evaporation. The organization of the lipidic matrix (bilayer versus solid-core arrangement) can have an impact on the distribution of the drug within the nanoparticle and influence loading and release properties. Drug release from solid lipid nanoparticles is determined by the nature of the lipidic component, particle size, and external physiological factors, which all can facilitate an accelerated or extended release of the target molecule (Akanda et al., 2023). In case of solid lipid nanoparticles, the main release mechanisms are diffusion through the lipid matrix and matrix erosion, allowing for sustained drug release and effective targeting. Thus, these nanoparticulate delivery systems bestow an excellent control over the release rate/site of the active agent, which ensures their therapeutic efficacy while reducing the chances of off-target effects (Akanda et al., 2023).

Moreover, the lipid formulation and particle size can precisely control the loading capacity and release dynamics of lipid-based nanoparticles. The lipids used have a significant impact on the affinity of the selected drug to the lipid matrix, the stability of the nanoparticles, and how they interact with the surrounding biological environment. The particle size affects the surface area/volume ratio, and smaller particles are generally more easily absorbed by the cells with a more rapid release potential, while larger nanoparticles can be characterized by more prolonged release profiles. Fine-tuning these parameters allows for the development of distinct release characteristics in lipids to fulfill various therapeutic needs, such as immediate or prolonged release. These parameters are extremely important in developing solid lipid formulations for oral and parenteral drug delivery systems since even small perturbations in the formulation parameters can lead to a highly controlled release of the drug at the expected sites (Basha et al., 2021).

Moreover, drug stability inside the lipid-based nanoparticles is a primary factor affect their performance during storage and biological routing. The lipid-based nanoparticles have been designed as a dosed vehicle to offer a physical barrier to the pharmaceutical agents against hydrolytic, oxidative and enzymatic degradation, which allows to prolong the shelf-life of labile compounds and ensure the product consistency during storage (Scioli Montoto et al., 2020). This property is particularly pronounced in solid lipid nanoparticles, in which dense lipid matrix significantly restricts molecular motion and molecular diffusion of water molecules or reactive species able to damage drug materials (Scioli Montoto et al., 2020). During biological administration, the lipid nanoparticles protect their cargo from exposure in aqueous biological media, so the potential drug loss or molecular transformation could be avoided before hitting the therapeutic target (Scioli Montoto et al., 2020). Therefore, the enhanced stability during storage and biological routing ensure the effective drug dosing from the nanoparticle carrier and the reduction of the therapeutic value loss due to material degradation (Scioli Montoto et al., 2020).

Advantages of Lipid-Based Nanoparticles in Drug Transport

The principal advantage of lipid-based nanoparticles as drug carriers is their ability to boost the solubility of poorly water-soluble drugs and to provide a protective effect to highly sensitive molecules that could be degraded by various factors. The controlled release pattern preserves more stable concentrations of drug in systemic circulation and prolongs dosing intervals. Enzymatic and chemical degradation of labile pharmaceutical compounds is prevented due to the lipid

matrix, which preserves the active ingredient from degradation until delivery to the site of action (García-Pinel et al., 2019). The nanometric size and lipid composition promote enhanced drug absorption through biological membranes, often leading to better therapeutic effect and higher bioavailability. The capacity of lipid-based nanoparticles to overcome the deficits characteristic of traditional drug carriers explains their expanding application in clinical practice, particularly for intricate or labile molecular entities (García-Pinel et al., 2019). The table-2 highlights the advantages and challenges of lipid-based nanoparticles. These nanoparticles improve drug solubility, enhance absorption, allow controlled release, and are generally safe because they use biocompatible lipids. However, challenges include stability issues during storage, difficulties in producing them consistently on a large scale, possible immune responses, and strict regulatory requirements. Overall, while lipid-based nanoparticles are very promising for advanced drug delivery, further improvements are needed to overcome technical and regulatory barriers.

Table 2: Advantages and Challenges of Lipid-Based Nanoparticles in Drug Delivery.

Advantages	Description	Challenges	Description
Improved Solubility & Bioavailability	Enhances delivery of poorly water-soluble drugs	**Stability Issues**	Risk of aggregation, leakage, or drug degradation during storage
Controlled & Sustained Release	Maintains steady therapeutic levels and reduces dosing frequency	**Scale-Up Manufacturing Difficulty**	Maintaining uniform size and encapsulation at industrial scale
Targeted Delivery	Can be surface-modified for tissue/organ-specific drug targeting	**Immunogenicity Concerns**	Repeated dosing may trigger immune activation in some patients
Biocompatibility & Low Toxicity	Lipids are naturally well-tolerated and safe	**Regulatory & Standardization Barriers**	Lack of universal testing and manufacturing standards delays approval

Also, lipid nanoparticles have a higher potential to improve drug bioavailability through more effective delivery of active pharmaceutical ingredients across biological membranes. Their surface properties and particle size offer significant physicochemical variations that improve bioavailability of active agents that otherwise present low solubility or are too unstable in common formulations. Its delivery may increase also the uptake into target cells, but that aspect can also be controlled through ligand alteration or by surface engineering to ensure targeting specific organs or tissues, such as malignant neoplasm or bacterial infection foci (Waheed et al., 2024). In this context, specific targeting facilitates lower systemic exposure and off-target effects, which correlate to high therapeutic responses and less adverse effects in patients. The improvement of drug bioavailability, along with organ/tissue targeting aspects, adds to the emerging role of lipid nanoparticles as a preferential approach towards sophisticated and tailored pharmaceutical strategies (Waheed et al., 2024).

In addition, the enhanced biocompatibility of lipid nanoparticles allows to emphasize their advantages over a number of other nanocarrier systems, design of which is currently under consideration. Being derived of lipids, which are compatible with the human body, the risk of immune or inflammatory reaction development remains lower for these nanocarriers, than for a number of promising alternatives, which have a complete therapeutic profile as a significant consequence. This allows to minimize the level of cytotoxicity associated with lipid nanoparticles, when compared to polymeric or inorganic carriers, which are capable to release potentially harmful degradation products or provoke undesirable cellular response (Mehta et al., 2023). In this regard, the higher level of tolerability allows to deliver a variety of therapeutic agents without compromising cellular viability and subsequently their performance. Therefore,

reduced level of toxicity allows to consider lipid nanoparticles as a platform with increased safety for drug delivery, as they can overcome numerous hurdles of other nanoscale drug carriers with respect to biocompatibility, thus contributing to wider clinical application and positive patient outcomes (Mehta et al., 2023).

Applications in Therapeutics

Among their beneficial characteristics, lipid-based nanoparticles have made significant advancements in various therapeutic areas, primarily in cancer treatment, infectious diseases, and prophylactic medicine. Numerous studies were carried upon solid lipid nanoparticles (SLNs) with anticancer drugs, where such systems improve the cellular uptake and therapeutic efficacy of cytotoxic agents by increasing drug retention in tumor tissues and reducing side effects in normal cells (Bayón-Cordero et al., 2019). In the area of infectious diseases, lipid-based nanoparticles promote the transport of antibiotics through stimulating the effective intracellular delivery, protecting the active compound from degradation, and decreasing antimicrobial resistance. Lipid nanocarriers can also be used as adjuvants or as vaccine delivery systems to improve the antigen presentation, thus promoting immunogenicity and extending duration of immune responses. These examples of lipid-based nanoparticles use demonstrate the successful implementation of their beneficial effects primarily in oncological, antimicrobial, and immunization approaches (Bayón-Cordero et al., 2019).

Moreover, lipid-based nanoparticles have revealed extensive capabilities for gene therapeutics, in particular for the delivery of nucleic acids (e.g. mRNA, siRNA, plasmid DNA). By protecting nucleic acids from enzymatic degradation, lipid nanoparticles (LNPs) improve uptake and transfection efficiency in target tissues. The adaptable core shell structures for lipid nanoparticles provide a means for the tunable adjustment of their composition and surface characteristics relevant to biological obstacles to the nucleic acid transport. Drawing on recent achievements, the opportunities for related platforms grow beyond vaccines with optimized lipid nanoparticle designs for their pharmacologically-acceptable dynamics to improve therapeutic efficiency (Verma et al., 2023). Therefore, lipid-based nanoparticles could become a major carrier in the genomic medicine area and progress the safe and effective gene-based therapeutics for clinical implications (Verma et al., 2023).

Furthermore, during the current years, successful translations of lipid-based nanoparticle formulations into clinic have been achieved, leading to the regulatory approval and clinical use of novel therapies. Among these formulations, lipid-mRNA nanoparticle emerged with unprecedented effectiveness as the first candidate platform for vaccines, leading to the first-ever mRNA-based vaccines to be delivered worldwide to mitigate the COVID-19 health crisis (Wang et al., 2021). The innovation highlights a joint effort across disciplines, where lipid chemistry, nanoparticle such as polymer research and clinical expertise could be placed together to serve the immediate need for public health. Beyond the area of vaccines, several formulations based on lipid nanoparticles for cancer chemotherapy and rare diseases have successfully moved from the lab into the regulations, creating milestone achievements for the drug delivery platform. The types of accomplishments obtained can reflect the effectiveness of the nanoscale vehicles to promote innovation on clinic therapy, encouraging for a more widespread usage of lipid nanoparticles formulations in both clinic preventive and therapeutic approaches (Wang et al., 2021).

Challenges and Limitations

In spite of the considerable successes, there are still specific significant scalability and stability challenges that hamper the further clinical development and translation of lipid-based nanoparticles (LNP). One of the prominent challenges in this area remains the inability to produce the nanoparticles at an eventual industrial scale which ensures reproducible

properties and encapsulation efficiency (Zheng et al., 2021). Among the stability challenges common for LNP formulations are nanoparticles aggregation, separation, and chemical degradation, including drug losses. These stability challenges may significantly reduce the reliability and therapeutic potential of the drug carrier, as well as its shelf-life and the overall clinical success. The necessity to underlie production and formulation dictates vectors usually enhances complexity, costs, and regulatory hurdles associated with the clinical development and translation of LNP formulations. Therefore, the comprehension and overcoming these challenges through advances in the formulations and production methodologies are crucial for the further enhancement of therapeutic performances of lipid-based nanoparticles (Zheng et al., 2021).

In addition, immunogenicity constitutes another major challenge of the clinical translation of lipid-based nanoparticles due to the fact that immune system activation is unwanted and may jeopardize the therapeutic effects. Though these delivery systems are usually composed of biocompatible lipids, repetitive administration cycles or surface engineering might lead to immune system sensitization or hypersensitivity responses in certain individuals (Gawne et al., 2023). Furthermore, accurate targeting constitutes another challenge associated with lipid-based nanoparticles, as it is crucial to correctly navigate these systems through the biological environment of the organism to the desired tissues, avoiding undesired biodistribution. This challenge relates to the heterogeneous nature of the targets and the current inter-individual differences, which may limit accurate targeting and decreased therapeutic outcomes. Hence, it remains a goal in the field for researchers to strike a balance between immune profile manipulation and the implementation of targeting approaches that allow for more accurate delivery of lipid-based nanoparticles to their targets (Gawne et al., 2023).

In addition, regulatory challenges coupled with the lack of standardized methodologies also pose critical challenges towards lipid-based nanoparticles acceptance in pharmaceutical establishment. The critical quality attributes of a product must be maintained and demonstration of product safety and consistency from implementation of suitable quality control principles is a challenge due to major constituent variations from the various available raw materials and processing techniques. The variations in initial formulation methods, specific analytical techniques employed for testing and the reproducibility of the nanoformulation from batch to batch, poses a challenge for achieving harmonization between various regulatory agencies further extending the duration and cost of product approval (Madkhali, 2022). Standardized manufacturing protocols for all lipid nanocarriers must be developed and applied to ensure reproducibility, stability and therapeutic effectiveness for any therapeutic base along with lipid-based nanoparticles. Tackling standardization and regulatory challenges is a prerequisite for achieving global acceptance along with enabling translational research from laboratories into clinics and commercial realization (Madkhali, 2022).

Future Perspectives and Innovations

In the near future, cutting-edge innovations in lipid-based nanoparticles will focus on the design of stimuli-responsive and multifunctional platforms with the ability to respond to changing physiological conditions. The stimuli-responsive lipid nanoparticles will be engineered to specifically release the therapeutic agent in the presence of designated stimuli (pH, temperature or enzymatic alterations), allowing targeted delivery and reducing exposure at non-target sites. Multifunctional lipid-based nanoparticles will also incorporate additional characteristics, such as targeting ligands, imaging agents or co-delivery of several therapeutics, capable of simultaneously revealing a therapeutic and diagnostic efficacy (theranostic approach) or exhibiting synergistic effects (Eygeris et al., 2021). One of the promising pathways in

the lipid nanoparticles design, particularly those used for RNA delivery, is the lipid chemistry, allowing a precise control of the stability, biodistribution and release profiles through molecular engineering of the lipid components. These trends indicate that the following generations of the lipid-based nanocarriers will become progressively important in addressing complex clinical requirements through the delivery of personalized, responsive and multifunctional solutions (Eygeris et al., 2021).

Moreover, current studies continue to explore modifications of lipid-based nanoparticles to overcome consortium's technological-therapeutic barriers. Researchers integrate new formulation concepts and approaches to increase encapsulation stability, delivery, targeting and navigation properties, related to complex organic molecules, including possibilities of delivering nucleic acid therapeutics, such as RNA and DNA. For instance, new engineering solutions contribute to lipid nanoparticles as a tool for now clinico-translational application for small interfering RNA (siRNA). Thus, the development of therapeutic delivery of lipid nanoparticles shows capability to conquer biological barriers, in cases when other strategies would hardly succeed. (Kulkarni et al., 2019) . Further research can create and engineered lipid-based nanoparticles with conceptually novelties, enhancing protection of active payload, reducing off-target effects, customizing properties to build a library of deliverable bioactives, expanded only by altering lipid composition. However, the prospects of lipid-based nanoparticles are most likely in a clinical enlargement of targeted indications, timely responding to growing beyond mentioned paradigmatic solutions for next-generation therapeutics of precision medicine. (Kulkarni et al., 2019).

Lastly, it has been predicted that the interplay of personalized medicine and the innovative solutions in nanotechnology can greatly impact the future of lipid-based drug delivery systems. Engineering the solid lipid nanoparticles (SLNs) by using the patient-specific data will allow the generation of novel approaches to the therapy with personalized parameters of dosage, release rates and biodistribution. Both of these approaches, when applied to complex diseases like cancer, can improve clinical performance and lead to the generation of new nanotechnologies targeting heterogeneity in a certain patient collective (Sivadasan et al., 2023). Using biodata for the production of lipid-based nanoparticles can enhance the delivery of pharmaceuticals to the target tissues, thus reducing side effects while increasing the therapeutic efficiency. Guided by the principles of personalized medicine, novel emerging innovations in nanotechnology can use lipid carriers in precision medicine approaches in the future (Sivadasan et al., 2023).

CONCLUSION

To conclude, lipid-based nanoparticles are the promising nanocarrier platforms that significantly tackle the major drawbacks of the conventional drug delivery systems such as poor solubility, limited stability, and non-specificity. This essay with the detailed analysis of the structural aspects, encapsulation mechanisms, and release profiles of lipid-based nanoparticles provides the evidence behind the elevated performance of such systems in delivering the drugs in a controllable, selective, and prolonged manner. Moreover, these carriers demonstrated their versatility in a wide range of applications from oncology to vaccine delivery and gene therapy, while addressing the issues of biocompatibility, immunogenicity, production, and particularities of regulatory control. The advances in engineering nanoparticles combined with the progress in personalized medicine and responsive design enabled the extension of horizons of their applicability. Further studies should be directed towards the improvement of targeting, biocompatibility, and manufacturing standards, which will ensure the wide use of lipid-based nanoparticles as the progressive tool in today’s and future pharmaceutical practice.

REFERENCES

1. Akanda, M., Mithu, M. S. H., & Douroumis, D., Solid lipid nanoparticles: An effective lipid-based technology for cancer treatment. *Journal of Drug Delivery Science and Technology*, 2023; *86*: 104709. https://www.sciencedirect.com/science/article/pii/S1773224723005610
2. Basha, S. K., Dhandayuthabani, R., Muzammil, M. S., & Kumari, V. S., Solid lipid nanoparticles for oral drug delivery. *Materials Today: Proceedings*, 2021; *36*: 313–324. https://www.sciencedirect.com/science/article/pii/S2214785320327243
3. Bayón-Cordero, L., Alkorta, I., & Arana, L., Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs. *Nanomaterials*, 2019; *9*(3): 474. https://www.mdpi.com/2079-4991/9/3/474
4. Eygeris, Y., Gupta, M., Kim, J., & Sahay, G., Chemistry of lipid nanoparticles for RNA delivery. *ACS Publications*, 2021; *55*(1): 2–12. https://doi.org/10.1021/acs.accounts.1c00544
5. García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., & López-Romero, J. M., Lipid-based nanoparticles: application and recent advances in cancer treatment. *Mdpi.Com*, 2019; *9*(4): 638. https://www.mdpi.com/2079-4991/9/4/638
6. Gawne, P. J., Ferreira, M., Papaluca, M., Grimm, J., & Decuzzi, P., New opportunities and old challenges in the clinical translation of nanotheranostics. *Nature Reviews Materials*, 2023; *8*(12): 783–798. https://www.nature.com/articles/s41578-023-00581-x
7. Kulkarni, J. A., Witzigmann, D., Chen, S., Cullis, P. R., & Van Der Meel, R., Lipid nanoparticle technology for clinical translation of siRNA therapeutics. *ACS Publications*, 2019; *52*(9): 2435–2444. https://doi.org/10.1021/acs.accounts.9b00368
8. Madkhali, O. A., Perspectives and prospective on solid lipid nanoparticles as drug delivery systems. *Molecules*, 2022; *27*(5): 1543. https://www.mdpi.com/1420-3049/27/5/1543
9. Mehta, M., Bui, T., Yang, X., Aksoy, Y., & Goldys, E., Lipid-based nanoparticles for drug/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. *ACS Publications*, 2023; *3*(6): 600–619. https://doi.org/10.1021/acsmaterialsau.3c00032
10. Musielak, E., Feliczak-Guzik, A., & Nowak, I., Synthesis and potential applications of lipid nanoparticles in medicine. *Materials*, 2022; *15*(2): 682. https://www.mdpi.com/1996-1944/15/2/682
11. Samimi, S., Maghsoudnia, N., & Eftekhari, R., Lipid-based nanoparticles for drug delivery systems. In *Characterization and biology of nanomaterials for drug delivery*, 2019; (pp.47–76). Elsevier. https://www.sciencedirect.com/science/article/pii/B9780128140314000039
12. Scioli Montoto, S., Muraca, G., & Ruiz, M. E., Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. *Frontiers in Molecular Biosciences*, 2020; *7*: 587997. https://doi.org/10.3389/fmolb.2020.587997
13. Sivadasan, D., Ramakrishnan, K., Mahendran, J., Ranganathan, H., Karuppaiah, A., & Rahman, H., Solid lipid nanoparticles: applications and prospects in cancer treatment. *International Journal of Molecular Sciences*, 2023; *24*(7): 6199. https://www.mdpi.com/1422-0067/24/7/6199
14. Utreja, P., Verma, S., Rahman, M., & Kumar, L., Use of nanoparticles in medicine. *Current Biochemical Engineering*, 2020; *6*(1): 7–24. https://doi.org/10.2174/2212711906666190724145101
15. Verma, M., Ozer, I., Xie, W., Gallagher, R., Teixeira, A., & Choy, M., The landscape for lipid-nanoparticle-based genomic medicines. *Nature.Com*, 2023; *22*(5): 349–350. https://www.nature.com/articles/d41573-023-00002-2

16. Waheed, I., Ali, A., Tabassum, H., Khatoon, N., Lai, W.-F., & Zhou, X., Lipid-based nanoparticles as drug delivery carriers for cancer therapy. *Frontiers in Oncology*, 2024; *14*: 1296091. https://pmc.ncbi.nlm.nih.gov/articles/PMC11040677/
17. Wang, C., Zhang, Y., & Dong, Y., Lipid nanoparticle–mRNA formulations for therapeutic applications. *Accounts of Chemical Research*, 2021; *54*(23): 4283–4293. https://doi.org/10.1021/acs.accounts.1c00550
18. Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C.-X., Lipid nanoparticles for drug delivery. *Wiley Online Library*, 2022a; *2*(2): 2100109. https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/anbr.202100109
19. Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C.-X., Lipid nanoparticles for drug delivery. *Wiley Online Library*, 2022b; *2*(2); 2100109. https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/anbr.202100109
20. Zheng, C., Li, M., & Ding, J., Challenges and opportunities of nanomedicines in clinical translation. *Scienceopen.Com*, 2021; *2*(2): 57. https://doi.org/10.15212/bioi-2021-0016